213 related articles for article (PubMed ID: 12620801)
21. Signals that dictate nuclear localization of human papillomavirus type 16 oncoprotein E6 in living cells.
Tao M; Kruhlak M; Xia S; Androphy E; Zheng ZM
J Virol; 2003 Dec; 77(24):13232-47. PubMed ID: 14645580
[TBL] [Abstract][Full Text] [Related]
22. Felis catus papillomavirus type-2 E6 binds to E6AP, promotes E6AP/p53 binding and enhances p53 proteasomal degradation.
Altamura G; Power K; Martano M; Degli Uberti B; Galiero G; De Luca G; Maiolino P; Borzacchiello G
Sci Rep; 2018 Dec; 8(1):17529. PubMed ID: 30510267
[TBL] [Abstract][Full Text] [Related]
23. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation.
Alarcón R; Koumenis C; Geyer RK; Maki CG; Giaccia AJ
Cancer Res; 1999 Dec; 59(24):6046-51. PubMed ID: 10626788
[TBL] [Abstract][Full Text] [Related]
24. A comparative analysis of the interactions of the E6 proteins from cutaneous and genital papillomaviruses with p53 and E6AP in correlation to their transforming potential.
Elbel M; Carl S; Spaderna S; Iftner T
Virology; 1997 Dec; 239(1):132-49. PubMed ID: 9426453
[TBL] [Abstract][Full Text] [Related]
25. HPV16 E6 confers p53-dependent and p53-independent phenotypes in the epidermis of mice deficient for E6AP.
Shai A; Nguyen ML; Wagstaff J; Jiang YH; Lambert PF
Oncogene; 2007 May; 26(23):3321-8. PubMed ID: 17130828
[TBL] [Abstract][Full Text] [Related]
26. Association of Bovine Papillomavirus Type 1 E6 oncoprotein with the focal adhesion protein paxillin through a conserved protein interaction motif.
Vande Pol SB; Brown MC; Turner CE
Oncogene; 1998 Jan; 16(1):43-52. PubMed ID: 9467941
[TBL] [Abstract][Full Text] [Related]
27. Quercetin induces G2 phase arrest and apoptosis with the activation of p53 in an E6 expression‑independent manner in HPV‑positive human cervical cancer‑derived cells.
Clemente-Soto AF; Salas-Vidal E; Milan-Pacheco C; Sánchez-Carranza JN; Peralta-Zaragoza O; González-Maya L
Mol Med Rep; 2019 Mar; 19(3):2097-2106. PubMed ID: 30664221
[TBL] [Abstract][Full Text] [Related]
28. Development of screening systems for drugs against human papillomavirus-associated cervical cancer: based on E6-E6AP binding.
Cho Y; Cho C; Joung O; Lee K; Park S; Yoon D
Antiviral Res; 2000 Sep; 47(3):199-206. PubMed ID: 10974372
[TBL] [Abstract][Full Text] [Related]
29. Targetting of the N-terminal domain of the human papillomavirus type 16 E6 oncoprotein with monomeric ScFvs blocks the E6-mediated degradation of cellular p53.
Giovane C; Trave G; Briones A; Lutz Y; Wasylyk B; Weiss E
J Mol Recognit; 1999; 12(2):141-52. PubMed ID: 10398405
[TBL] [Abstract][Full Text] [Related]
30. HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background.
Massimi P; Shai A; Lambert P; Banks L
Oncogene; 2008 Mar; 27(12):1800-4. PubMed ID: 17934525
[TBL] [Abstract][Full Text] [Related]
31. Structure based identification and characterization of flavonoids that disrupt human papillomavirus-16 E6 function.
Cherry JJ; Rietz A; Malinkevich A; Liu Y; Xie M; Bartolowits M; Davisson VJ; Baleja JD; Androphy EJ
PLoS One; 2013; 8(12):e84506. PubMed ID: 24376816
[TBL] [Abstract][Full Text] [Related]
32. The stability of the human papillomavirus E6 oncoprotein is E6AP dependent.
Tomaić V; Pim D; Banks L
Virology; 2009 Oct; 393(1):7-10. PubMed ID: 19700180
[TBL] [Abstract][Full Text] [Related]
33. Structure of the p53 degradation complex from HPV16.
Wang JCK; Baddock HT; Mafi A; Foe IT; Bratkowski M; Lin TY; Jensvold ZD; Preciado López M; Stokoe D; Eaton D; Hao Q; Nile AH
Nat Commun; 2024 Feb; 15(1):1842. PubMed ID: 38418456
[TBL] [Abstract][Full Text] [Related]
34. A ubiquitin variant-based affinity approach selectively identifies substrates of the ubiquitin ligase E6AP in complex with HPV-11 E6 or HPV-16 E6.
Ebner FA; Sailer C; Eichbichler D; Jansen J; Sladewska-Marquardt A; Stengel F; Scheffner M
J Biol Chem; 2020 Oct; 295(44):15070-15082. PubMed ID: 32855237
[TBL] [Abstract][Full Text] [Related]
35. The role of exogenous p53 and E6 oncoproteins in in vitro transformation by bovine papillomavirus type 4 (BPV-4): significance of the absence of an E6 ORF in the BPV-4 genome.
Scobie L; Jackson ME; Campo MS
J Gen Virol; 1997 Nov; 78 ( Pt 11)():3001-8. PubMed ID: 9367387
[TBL] [Abstract][Full Text] [Related]
36. E6 proteins from high-risk HPV, low-risk HPV, and animal papillomaviruses activate the Wnt/β-catenin pathway through E6AP-dependent degradation of NHERF1.
Drews CM; Case S; Vande Pol SB
PLoS Pathog; 2019 Apr; 15(4):e1007575. PubMed ID: 31002735
[TBL] [Abstract][Full Text] [Related]
37. Human papillomavirus E6 regulates the cytoskeleton dynamics of keratinocytes through targeted degradation of p53.
Cooper B; Brimer N; Vande Pol SB
J Virol; 2007 Nov; 81(22):12675-9. PubMed ID: 17804489
[TBL] [Abstract][Full Text] [Related]
38. Solution structure determination and mutational analysis of the papillomavirus E6 interacting peptide of E6AP.
Be X; Hong Y; Wei J; Androphy EJ; Chen JJ; Baleja JD
Biochemistry; 2001 Feb; 40(5):1293-9. PubMed ID: 11170455
[TBL] [Abstract][Full Text] [Related]
39. Deciphering the mechanisms of HPV E6 mutations in the destabilization of E6/E6AP/p53 complex.
Li L; Dong X; Tang Y; Lao Z; Li X; Lei J; Wei G
Biophys J; 2022 May; 121(9):1704-1714. PubMed ID: 35364103
[TBL] [Abstract][Full Text] [Related]
40. The E6AP binding pocket of the HPV16 E6 oncoprotein provides a docking site for a small inhibitory peptide unrelated to E6AP, indicating druggability of E6.
Zanier K; Stutz C; Kintscher S; Reinz E; Sehr P; Bulkescher J; Hoppe-Seyler K; Travé G; Hoppe-Seyler F
PLoS One; 2014; 9(11):e112514. PubMed ID: 25383876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
